Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection.
about
Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelinesSynthesis and Anti-Hepatitis B Virus and Anti-Hepatitis C Virus Activities of 7-Deazaneplanocin A Analogues in VitroDetection and analysis of resistance mutations of hepatitis B virusMolecular characterization of occult hepatitis B virus infection in patients with end-stage liver disease in Colombia.Screening and identification of compounds with antiviral activity against hepatitis B virus using a safe compound library and novel real-time immune-absorbance PCR-based high throughput system.Long-term outcomes and dynamics of mutants associated with lamivudine-adefovir rescue therapy in patients with lamivudine-resistant chronic hepatitis B.HBV and HCV therapy.Emerging drugs for hepatitis B.Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine.Management of hepatitis B in developing countries.Antiviral therapy of chronic hepatitis B: can we clear the virus and prevent drug resistance?Achievements and challenges in antiviral drug discovery.A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine.Optimized combination therapies with adefovir dipivoxil (ADV) and lamivudine, telbivudine, or entecavir may be effective for chronic hepatitis B patients with a suboptimal response to ADV monotherapy.Management of chronic hepatitis B: consensus guidelinesVirologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach.Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen.Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade.Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections.Treatment of hepatitis B virus-infected patients: utility of therapeutic recommendations in developing countries.Comparative evaluation of long-term monotherapies & combination therapies in patients with chronic hepatitis B: A pilot study.Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B.Differences in sequences between HBV-relaxed circular DNA and covalently closed circular DNA.In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine.Emergence of a novel mutation in the FLLA region of hepatitis B virus during lamivudine therapy.Factors associated with poor adherence to antiviral treatment for hepatitis B.The clinical implication of single nucleotide polymorphisms in deoxycytidine kinase in chronic hepatitis B patients treated with lamivudine.The hepatitis B virus (HBV) HBx protein activates AKT to simultaneously regulate HBV replication and hepatocyte survival.Profound antiviral effect of oral administration of MIV-210 on chronic hepadnaviral infection in a woodchuck model of hepatitis BMicroarray for hepatitis B virus genotyping and detection of 994 mutations along the genome.Current treatment indications and strategies in chronic hepatitis B virus infection.Hepatitis B virus genotyping among chronic hepatitis B patients with resistance to treatment with lamivudine in the City of Ribeirão Preto, State of São Paulo.Comparative analysis of viral genomes from acute and chronic hepatitis B reveals novel variants associated with a lower rate of chronicity.Hepatitis B virus drug resistance to current nucleos(t)ide analogs: Mechanisms and mutation sites.Entecavir.Pathogenesis of hepatitis B virus infection.Pre-existing YMDD mutants in treatment-naïve patients with chronic hepatitis B are not selected during lamivudine therapy.
P2860
Q27000080-52CCA141-C284-46CE-B224-97945E7CC0ECQ27489125-C9FE4094-B95B-4861-B571-D03C5BCD23F0Q28266666-B4900953-8D29-4A29-8C4D-81001C80CBBEQ33883921-E7CF9D1A-A8F6-4F47-8CEA-DD9972D166CCQ34588956-64265941-74F0-4046-8F0A-6C9BAF0F8E5CQ34809263-556C29C4-69A7-479C-BB71-7C7E5D5AE1BFQ35259824-8263CA98-2A42-4B53-B216-8BE094928894Q35359369-9A5DC120-0045-4840-AEEF-067F84E99A46Q35473087-E050BD24-5D67-4777-9BCA-F2DA60D78DC6Q35635637-6A622E01-3192-4DEB-A9A2-A908A81F6345Q36007344-8DAB6259-891C-4054-9C65-CF54BB3DB3ECQ36186792-9C4AFF3C-0EE3-4233-98FC-0ACFA7FF200BQ36445386-3CB16B21-2EA7-4C30-B7B4-55D2D33E54F8Q36492959-08636B36-8D90-42FA-AEA1-07DFE9C8825CQ36849343-07AE4159-5AE6-4DFD-8A1C-D7233A2E5E37Q37074608-DCCEA470-A399-45CA-9230-AE14DEF3CF3AQ37099761-3F2D29E7-7388-4E61-9ACA-3396E5638763Q37229851-E4AEF885-C1FE-4326-ACE5-16E62683ECEBQ37465040-DC407D09-E8D7-4B8B-BA85-466370432B59Q37508051-370D6AE3-3568-427F-8028-FDC0BAFA1C74Q37658659-ECBE3B83-6B3C-4F71-A2A3-8A19607AF0E9Q37934571-67897B02-0045-4C2F-89F2-9DDA49E7B29CQ40152038-6A31B615-48D4-4B1A-834D-2EB1173E3EBFQ40157026-ADBF8F45-1CFE-4F03-9F51-F19BFEDA935EQ40312810-5D008111-B129-48E4-9D76-98A503CE33D9Q40404519-CCD2DC43-2E0E-4241-B103-80A4070D36CDQ40583804-CD0AD819-480D-4173-A203-BF87B59A6F78Q41327802-CA2F6EF6-74E9-4CE2-822C-F5728FC13FBEQ41684662-83FFDF78-EFBB-4C2F-BA5E-687C6129F5E9Q42004056-1CCADC8F-69DD-42AC-BEA4-0DD7E59B4991Q42571412-C3BD0BD5-6404-41CE-AD74-988E4C8D7805Q42619923-378498C2-DEF7-41DD-9C70-8778DFD7AD03Q43012086-BBC3A945-2F1E-4133-9012-D72F0EB82D94Q43717709-F9B3AA76-C340-44D8-8387-A29674A451B3Q45363333-543C88EF-67CA-43CD-86B4-D703ADFBBE21Q46631010-3D7CC4C3-8AA2-4A1D-9A71-97E8A8340866Q52928127-1C371BEF-FD4C-4FE7-9F89-0A0EA662BCBFQ54334001-1739AF7E-0452-43D4-809B-CF641BBC2EC8
P2860
Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Mechanism of viral persistence ...... c hepatitis B virus infection.
@ast
Mechanism of viral persistence ...... c hepatitis B virus infection.
@en
type
label
Mechanism of viral persistence ...... c hepatitis B virus infection.
@ast
Mechanism of viral persistence ...... c hepatitis B virus infection.
@en
prefLabel
Mechanism of viral persistence ...... c hepatitis B virus infection.
@ast
Mechanism of viral persistence ...... c hepatitis B virus infection.
@en
P1433
P1476
Mechanism of viral persistence ...... c hepatitis B virus infection.
@en
P2093
Fabien Zoulim
P356
10.1016/S0166-3542(04)00162-7
P577
2004-10-01T00:00:00Z